The American Journal of Human Genetics, Volume 107

## **Supplemental Data**

## Human iPSC Modeling Reveals Mutation-Specific

## **Responses to Gene Therapy in a Genotypically**

## **Diverse Dominant Maculopathy**

Divya Sinha, Benjamin Steyer, Pawan K. Shahi, Katherine P. Mueller, Rasa Valiauga, Kimberly L. Edwards, Cole Bacig, Stephanie S. Steltzer, Sandhya Srinivasan, Amr Abdeen, Evan Cory, Viswesh Periyasamy, Alireza Fotuhi Siahpirani, Edwin M. Stone, Budd A. Tucker, Sushmita Roy, Bikash R. Pattnaik, Krishanu Saha, and David M. Gamm



Figure S1. Characterization of iPSC-RPE. (A) Karyotype analysis for ARB iPSCs. (B) DNA sequencing confirming p.Arg141His and p.Ala195Val encoding mutations in ARB iPSCs. (C) Net transepithelial electrical resistance (TER) ( $\Omega \cdot cm^2$ ) for iPSC-RPE from all six lines. The dashed line demarcates the minimum expected TER (150  $\Omega \cdot cm^2$ ). Replicates: n=12 for each line (4 transwells from 3 replicates each), error bars represent mean ± SD. (D) Gene expression analysis (RT-PCR) of selected RPE-specific markers in all six lines. (E-J) Chloride current traces, measured in the presence (*black*) or absence (*gray*) of calcium over a voltage ramp (-100 to +100 mV), that were used to generate CaCC current density plots in Figure 1E. 4.5  $\mu$ M calcium was used for +calcium conditions. The number (n) of individual cells patch clamped in the presence or absence of calcium in order to calculate CaCC current densities is shown in the top left corner of each graph. Data were obtained from at least two replicates. Error bars represent mean ± SEM.



Figure S2. Gene augmentation (GA) restores CaCC function in ARB iPSC-RPE, and Arg218Cys and Asn296His adBD iPSC-RPE, but not in Ala146Lys adBD iPSC-RPE. (A) GFP fluorescence in Arg141His/Ala195Val ARB iPSC-RPE transduced with lentivirus expressing BEST1. Scale bar =  $100 \,\mu\text{m}$ . (B) ICC analysis of BEST1 and ZO-1 in Arg141His/Ala195Val iPSC-RPE transduced with lentivirus expressing BEST1. Increased BEST1 levels are observed in Arg141His/Ala195Val iPSC-RPE cells following gene augmentation. Scale bar =  $50 \mu m$  (applies to both images). (C) Representative western blot showing levels of BEST1 in iPSC-RPE. Protein samples from the rhodopsin degradation assays were used to assess BEST1 levels. (D) GFP fluorescence in adBD iPSC-RPE transduced with lentivirus expressing *BEST1*. Scale bar = 100 μm (applies to all three images). (E) Chloride current traces of Arg141His/Ala195Val iPSC-RPE after gene augmentation measured in the presence (*black*) or absence (*grav*) of calcium. Error bars represent mean ± SEM. (F-H) Chloride current traces for adBD iPSC-RPE after gene augmentation, measured in the presence (black) or absence (gray) of calcium over a voltage ramp (-100 to +100 mV), that were used to obtain CaCC current density. 4.5  $\mu$ M calcium was used for +calcium conditions. Cells with green fluorescence were used for all patch clamp measurements after gene augmentation. The number (n) of individual cells patch clamped in the presence or absence of calcium (in order to calculate CaCC current densities) is shown in the top left corner of each graph. Data were obtained from at least two replicates. Error bars represent mean  $\pm$  SEM. (I-L) Western blots used for the rhodopsin degradation assay (left), and corresponding grayscale images (right) of western blots used to quantify levels of rhodopsin shown in Figures 2 and 3 (boxes represent areas used for quantification). For each lane, the boxed area was selected to include bands corresponding to fully denatured rhodopsin and its aggregated forms.



Figure S3. Gene editing (GE) restores CaCC activity in iPSC-RPE from all tested adBD lines. (A-D) Chloride current traces, measured in the presence (*black*) or absence (*gray*) of calcium over a voltage ramp (-100 to +100 mV), that were used to calculate CaCC current density plots after gene editing of adBD iPSC-RPE. iPSC-RPE was edited using lentiviral genome editors encoding sgRNAs that target (A) the *AAVS1* site in Ala146Lys adBD iPSC-RPE, or (B-D) *BEST1* mutation sites in (B) Ala146Lys adBD iPSC-RPE, (C) Asn296His adBD iPSC-RPE, or (D) Arg218Cys adBD iPSC-RPE. Cells with GFP fluorescence were used for whole cell patch clamp measurements and 4.5  $\mu$ M calcium was used for +calcium conditions. The number (n) of individual cells patch clamped with or without calcium is shown at the top left corner of each graph. Data were obtained from two replicates. Error bars represent mean ± SEM.





Figure S4. Single cell transcriptome analysis in gene-edited adBD iPSC-RPE. (A) Percent of analyzed cells per sample for which spCas9-T2A-GFP transcripts were captured using scRNAseq. (B) Dendrogram depicting relative similarity between samples. Non-negative matrix factorization comparison across samples indicates that greater transcriptional variability exists between iPSC-RPE lines than in the same iPSC-RPE line treated with lentiviral genome editors (AAVS1 lentiviral genome editor versus BEST1 mutant allele-targeted lentiviral genome editor). The dendrogram shows the similarity of the transcriptomes from each sample, derived from the average Jaccard coefficient between gene clusters from one sample and those from another sample. The y-axis denotes 1-average Jaccard coefficient and indicates the distance between different samples (tree tips) as well as between groups of samples (internal nodes). (C) Differential gene expression in 5 curated gene sets associated with cell cycle regulation (circles), apoptosis (triangles), DNA damage response (diamonds), innate immune response (asterisks), or RPEidentity (squares) in control (AAVS1) lentiviral genome editor versus mutant allele-targeted lentiviral genome editor treated samples. For one sample pair (Asn296His iPSC-RPE), genes associated with a potential adverse treatment effect were upregulated in control lentiviral genome editor-treated sample compared to the mutant allele-targeted lentiviral genome editor sgRNAtreated sample. p < 0.01 was the threshold for determining significant changes in gene expression.

Gene	Forward Primer	Reverse Primer		
BEST1	ATTTATAGGCTGGCCCTCACGGAA	TGTTCTGCCGGAGTCATAAAGCCT		
MITF	TTCACGAGCGTCCTGTATGCAGAT	TTGCAAAGCAGGATCCATCAAGCC		
PEDF	AATCCATCATTCACCGGGCTCTCT	TGCACCCAGTTGTTGATCTCTTGC		
RPE65	GCCCTCCTGCACAAGTTTGACTTT	AGTTGGTCTCTGTGCAAGCGTAGT		
OCCLUDIN	TCATTGCCGCGTTGGTGATCTTTG	ATGATGCCCAGGATAGCACTCACT		
CRALBP	TTCCGCATGGTACCTGAAGAGGAA	ACTGCAGCCGGAAATTCACATAGC		
GAPDH	CAACGGATTTGGTCGTATTGG	GCAACAATATCCACTTTACCACAGTTAA		

 Table S1: RPE-specific RT-PCR primers used.

<b>GE Vector Name</b>	sgRNA Name	Vector Backbone	<b>Backbone Source</b>			
VMD2.AAVS1	AAVSI	VMD2-spCas9-T2A-GFP	Alfred Lewin (University of Florida)			
VMD2.R218C	R218C	VMD2-spCas9-T2A-GFP	Alfred Lewin (University of Florida)			
VMD2.N296H	N296H	VMD2-spCas9-T2A-GFP	Alfred Lewin (University of Florida)			
VMD2.A146K	A146K	VMD2-spCas9-T2A-GFP	Alfred Lewin (University of Florida)			

Table S2. List of gene editing vectors used.

Primer Name	Primer sequence		
LCv2-GFP.Gib.F	GATTACAAAGACGATGACGATAAGGGATCCGGTGAGGGCAGA		
	GGAAGTC		
LCv2-GFP.Gib.	ACAGTCGAGGCTGATCAGCGGGTTTAAACCTACTACTGCTAGA		
	GATTTTCCACAC		
LCv2-GFP.seq.L	ACCGGCCTGTACGAGACACG		
LCv2-GFP.seq.R	GAAAGGACAGTGGGAGTGGCACC		
VMD2.LCv2.GF	GTGGCACCGAGTCGGTGCTTTTTTGAATTCCAATTCTGTCATTTT		
P.Gib.F	ACTAGGGTGATGAAATTC		
VMD2.LCv2.GF	TGTACTTCTTGTCCATGGTGGCAGCGCTCTATCGGCCGCGGGTA		
P.Gib.R	CA		
VMD2.LCv2.GF	GAATGAATACCGGGCTGCAGTCAAC		
P.seq.L			
VMD2.LCv2.GF	GTCGGTGATCACGGCCCAG		
P.seq.R			

 Table S3. List of primers for lentiviral plasmid generation.

						Off-	On-
sgRNA						Target	Target
Name	Sequence 5' - 3'	PAM	Chr	Position	Strand	Score	Score
A146K	CTTTGGTGCTGACGCTGCGC	AGG	11	61955893	-1	81.2	51.6
R218C	GTGTCCACACTGAGTACACA	AGG	11	61957403	-1	56.3	67.2
N296H	CATCATCCTCTCCAAAGGGG	TGG	11	61959521	-1	54.0	64.6
AAVSI	GGGGCCACTAGGGACAGGAT	TGG	19	55115755	+1	55.8	54.5

**Table S4.** List of sgRNAs. Off-target <sup>47</sup> and on-target <sup>48</sup> scores are also presented. Scores range from 0-100 with higher scores being better for both scoring systems. Highest ranked off-target cut sites for each sgRNA are available in Supplemental Data File C.

Primer Name	Primer sequence	
MT.C.OT.5v2.HTS.F	GTTGGTTCCTGAAGATGGGCAG	
MT.C.OT.5v2.HTS.R	CTGTCAAGGCCAAGTTCTGCTG	
MT.C.OT.2.HTS.F	GCTAAATTCTGCTATAAAAGGAAGG	
MT.C.OT.2.HTS.R	GCATTGCTTTAGAAAACTCAGAAGT	
MT.C.OT.3.HTS.F	AGTGAGACCAAGTTCTGACAGCA	
MT.C.OT.3.HTS.R	GGCCTCTTCATACATACACATGCAC	
MT.C.OT.4.HTS.F	CCTCCACATCTGCAGAAAAGTGT	
MT.C.OT.4.HTS.R	GGCAGGGTTTGGTCTCCTACTT	
MT.C.OT.5.HTS.F	GGATGGCTCTGGGTGGGTTT	
MT.C.OT.5.HTS.R	CTTCCAACTCTTCCTCCCACCC	
MT.C.OT.6.HTS.F	TGAGGTTCAGAATAGCTCAGCA	
MT.C.OT.6.HTS.R	TGTTTCTGTGAAGCAAATCAAAGCT	
MT.C.OT.7.HTS.F	TGTTTCTGTGAAGCAAATCAAAGCT	
MT.C.OT.7.HTS.R	TGAGGTTCAGAATAGCTCAGCA	
MT.C.OT.8.HTS.F	AAAGCATGGCGGGAGTGCTAA	
MT.C.OT.8.HTS.R	TGACTAAATCCCTGGCATCGCT	
MT.C.OT.9.HTS.F	GCCAGTAATTTTCCAAGGCTTCT	
MT.C.OT.9.HTS.R	TTCCTACTAGAACCTCCTTGAG	
MT.C.OT.10.HTS.F	GTGACCTGACTTTGCTGAAAGGT	
MT.C.OT.10.HTS.R	ACCTGAATTATCTCAAGCTCACT	
AAVS1T2.HTS.F	ATGTGGCTCTGGTTCTGGGTAC	
AAVS1T2.HTS.R	GAGACTAGGAAGGAGGAGGCCT	
R218C.HTSv2.F	GTGTTCAGAACCCCATCCCC	
R218C.HTSv2.R	AGCCTAGTCCTCACCTGTGT	
BEST.cDNA.HTSv2.F	GGTCGAATCCGGGACCCTATC	
BEST.cDNA.HTSv2.R	GCCACAGTCACCACCTGTGTAT	
AAVS1T2.HTS.F	ATGTGGCTCTGGTTCTGGGTAC	
AAVS1T2.HTS.R	GAGACTAGGAAGGAGGAGGCCT	

**Table S5.** Primers for deep sequencing of DNA and cDNA.

Lentivirus	Titer (Transduction units/ml)*
VMD2-BEST1-T2A-GFP	$22.00 \text{ x} 10^7$
<i>VMD2-spCas9-T2A-GFP</i> R218C sgRNA (encodes sgRNA targeting the c.652C>T (p.Arg218Cys) mutant <i>BEST1</i> allele)	74.16 x10 <sup>7</sup>
<i>VMD2-spCas9-T2A-GFP</i> A146K sgRNA (encodes sgRNA targeting the c.436_437delinsAA (p.Ala146Lys) mutant <i>BEST1</i> allele)	74.26 x10 <sup>7</sup>
<i>VMD2-spCas9-T2A-GFP</i> N296H sgRNA (encodes sgRNA targeting the c.886A>C (p.Asn296His) mutant <i>BEST1</i> allele)	68.91 x10 <sup>7</sup>
<i>VMD2-spCas9-T2A-GFP AAVS1</i> sgRNA (encodes sgRNA targeting <i>AAVS1</i> alleles)	74.01 x10 <sup>7</sup>

\*The QuickTiter Lentivirus Titer Kit calculates Transduction units in 10-fold ranges (10<sup>6-7</sup>).

Table S6. Titers for lentivirus stocks used in this study.